. 2019 Jan 28;18:2325958218823530. doi: 10.1177/2325958218823530

Table 2.

Key PMTCT Interventions Received by Categories of Women (“Retested” versus “Initially” Tested HIV+).

Among Women Who Were HIV Positive at Retest (n = 55)	Among Women Who Were HIV Positive at the Initial Test (n = 2165)
Access to ARVs for PMTCT; of the 55: 47 (85.5%) received any ARV regime 44 (80.0%) received AZT + NVP^a 2 (3.6%) received triple ARV regime^b 1 (1.8%) received sdNVP^c 0 (0.0%) unspecified ARV regimen 8 (14.5%) received no ARVs	Access to ARVs for PMTCT; of the 2165: 1981 (91.5%) received any ARV regime 1764 (81.5%) received AZT + NVP^a 192 (8.9%) received triple ARV regime^b 0 (0.0%) received sdNVP^c 25 (1.2%) unspecified ARV regimen 184 (8.5%) received no ARVs
A total of 24 (43.6%) women had a CD4 test performed and results available; the median CD4 count was 571 cells/mm³ (IQR: 444-773). Of their HIV-exposed infants, 4 (7.3%) received ARV prophylaxis and 39 (70.9%) were reportedly exclusively breastfed for the first 6 months of life. A total of 36 exposed infants accessed HIV “early infant diagnosis” (EID) and had their results available. The median age at the time of the dried blood collection for EID was 10 weeks ranging^d from 2 to 58 weeks; 4 (11.1%) were HIV positive of the 36 EID results.	A total of 1759 (81.2%) women had a CD4 test performed and results available; the median CD4 count was 395 cells/mm³ (IQR: 271-550). Of their HIV-exposed infants, 27 (1.3%) received ARV prophylaxis and 906 (41.8%) were reportedly exclusively breastfed for the first 6 months of life. A total of 853 exposed infants accessed EID and had their results available. The median age at the time of the dried blood collection for EID was 7 weeks ranging^d from 2 to 111 weeks; 27 (3.2%) were HIV positive of the 853 EID results.

Among Women Who Were HIV Positive at Retest (n = 55)

Among Women Who Were HIV Positive at the Initial Test (n = 2165)

Access to ARVs for PMTCT; of the 55:

47 (85.5%) received any ARV regime
44 (80.0%) received AZT + NVP^a
2 (3.6%) received triple ARV regime^b
1 (1.8%) received sdNVP^c
0 (0.0%) unspecified ARV regimen
8 (14.5%) received no ARVs

Access to ARVs for PMTCT; of the 2165:

1981 (91.5%) received any ARV regime
1764 (81.5%) received AZT + NVP^a
192 (8.9%) received triple ARV regime^b
0 (0.0%) received sdNVP^c
25 (1.2%) unspecified ARV regimen
184 (8.5%) received no ARVs

A total of 24 (43.6%) women had a CD4 test performed and results available; the median CD4 count was 571 cells/mm³ (IQR: 444-773).
Of their HIV-exposed infants, 4 (7.3%) received ARV prophylaxis and 39 (70.9%) were reportedly exclusively breastfed for the first 6 months of life.
A total of 36 exposed infants accessed HIV “early infant diagnosis” (EID) and had their results available. The median age at the time of the dried blood collection for EID was 10 weeks ranging^d from 2 to 58 weeks; 4 (11.1%) were HIV positive of the 36 EID results.

A total of 1759 (81.2%) women had a CD4 test performed and results available; the median CD4 count was 395 cells/mm³ (IQR: 271-550).
Of their HIV-exposed infants, 27 (1.3%) received ARV prophylaxis and 906 (41.8%) were reportedly exclusively breastfed for the first 6 months of life.
A total of 853 exposed infants accessed EID and had their results available. The median age at the time of the dried blood collection for EID was 7 weeks ranging^d from 2 to 111 weeks; 27 (3.2%) were HIV positive of the 853 EID results.

Abbreviations: ARV, antiretrovirals; EID, early infant diagnosis; IQR, interquartile range; PMTCT, prevention of mother-to-child transmission; sdNVP, single-dose nevirapine.

^a This consists of zidovudine (AZT) 300 mg + nevirapine (NVP) twice a day.

^b This is a highly active antiretroviral therapy comprised of AZT + lamivudine (3TC) + NVP.

^c sdNVP is a single dose of NVP (200 mg) at the onset of labor.

^dAuthors believe that this huge range is the reflection of the known huge turnaround time between the blood sample collection and the availability of results to the health providers.